Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease.
Merry
C
C
Mulcahy
F
F
Barry
M
M
Gibbons
S
S
Back
D
D
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use; D008099:Liver / Q000201:enzymology; D008297:Male; D008874:Midazolam / Q000627:therapeutic use*; D019258:Saquinavir / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage / Q000627:therapeutic use; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D006993:Hypnotics and Sedatives; D019259:Lamivudine; D015215:Zidovudine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D003577:Cytochrome P-450 Enzyme System; D019258:Saquinavir; D008874:Midazolam